Please find the enclosed intimation of the Company as per the captioned subject for reference.

Regulatory product approvalBusiness Updates View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹8592.00

prior close

₹8639.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-1.3% vs market

Pharmaceuticals peers, median of 160sector+0.2%-0.3% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

-0.2

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.1-1.3+0.2-0.3

Next day

-0.2+1.2-1.4+0.2-0.3

+1.9+2.8-0.9+1.4+0.5

+5.0+3.5+1.5+1.3+3.7

+0.2+3.5-3.3+1.6-1.4

-1.3+2.8-4.1+1.0-2.3

+0.8+2.8-2.0+0.2+0.6

15d

-4.2+4.2-8.4+0.7-4.9

-0.2+10.1-10.3+3.1-3.3

-6.1+10.0-16.1+7.2-13.3

-13.9+14.6-28.4+8.2-22.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has received permission from CDSCO (Central Drugs Standard Control Organization) to import and distribute Acalabrutinib maleate tablets 100mg (Brand: Calquence®) for an additional indication. The drug is now approved for use in combination with Bendamustine and Rituximab (BR) to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval expands the therapeutic scope of Calquence® in the Indian market, subject to any related statutory approvals that may be required. The permission was received on May 20, 2026, and the company submitted the intimation to stock exchanges on May 21, 2026.

Likely market impact

This regulatory approval expands Calquence®'s addressable patient population in India, potentially boosting revenue for AstraZeneca Pharma India. Positive development for shareholders as it strengthens the company's oncology portfolio in the Indian market.